Current Insights into Ovarian Cancer: Epidemiology, Diagnosis, and Treatment
DOI:
https://doi.org/10.12775/QS.2025.44.62840Keywords
Ovarian cancer, epidemiology, diagnosis, staging, treatment, personalized medicine, biomarkers, prognosis, PARP inhibitors, immunotherapy, genetic testingAbstract
Ovarian cancer remains one of the deadliest gynecological cancers worldwide. This review summarizes recent findings on its epidemiology, diagnosis, staging, treatment, and future directions. Despite scientific progress, ovarian cancer is still often detected at advanced stages due to vague symptoms and lack of effective early screening. This paper draws from recent studies, guidelines, and databases to outline current trends, molecular mechanisms, and diagnostic methods such as imaging and biomarkers. Surgery combined with platinum-based chemotherapy remains standard care, while genetic profiling and PARP inhibitors mark advances in personalized treatment. Challenges like drug resistance, healthcare disparities, and the lack of early detection persist, urging development of better diagnostic tools and broader access to targeted therapies and immunotherapy. Future research should focus on simple screening tests, deeper understanding of tumor biology, and universal genetic testing availability. Although management has improved, timely detection and individualized treatment are vital. Continued research and better healthcare infrastructure are key to improving survival and quality of life for ovarian cancer patients.
References
Ahmad, S., Rehman, W. U., Shaukat, M. T., Rehman, A. U., Mohsin, A., & Dizon, D. S. (2024). Country and continent-wise trends in mortality rates of ovarian cancer from 1980-2021: An analysis of GBD study 2021. JCO Oncology Practice, 20(10_suppl), 148–148. https://doi.org/10.1200/op.2024.20.10_suppl.148
Ali, A. T., Osamah Al-ani, & Faisal Al-ani. (2023). Epidemiology and risk factors for ovarian cancer. Menopausal Review, 22(2), 93–104. https://doi.org/10.5114/pm.2023.128661
Balan, D., Kampan, N. C., Plebanski, M., & Abd Aziz, N. H. (2024). Unlocking ovarian cancer heterogeneity: advancing immunotherapy through single-cell transcriptomics. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1388663
Chakraborty, S., Shenoy, P. S., Mehrotra, M., Pratham Phadte, Singh, P., Rekhi, B., & Ray, P. (2023). Through the Looking Glass: Updated Insights on Ovarian Cancer Diagnostics. Diagnostics, 13(4), 713–713. https://doi.org/10.3390/diagnostics13040713
El-Shakankery, K. H., Kefas, J., Palmer, K., Houston, A., Mukherjee, U., Gao, K., Tan, W., Crusz, S. M., Flynn, M. J., Ledermann, J. A., Lockley, M., McCormack, M., MacDonald, N., Nicum, S., Devlin, M. J., & Miller, R. E. (2024). Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London. Cancers, 16(21), 3590. https://doi.org/10.3390/cancers16213590
Ghose, A., McCann, L., Shania Makker, Mukherjee, U., Gullapalli, N., Jayaraj Erekkath, Shih, S., Mahajan, I., Sanchez, E., Uccello, M., Moschetta, M., Adeleke, S., & Stergios Boussios. (2024). Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241233225
Hardikar, N. S. (2022). The Importance of Early Detection of Ovarian Cancer: Epidemiology and Risk Factors. Basic & Clinical Cancer Research. https://doi.org/10.18502/bccr.v13i3.11405
Hockings, H., & Miller, R. E. (2023). The role of PARP inhibitor combination therapy in ovarian cancer. Therapeutic Advances in Medical Oncology, 15. https://doi.org/10.1177/17588359231173183
Hong, M.-K., & Ding, D.-C. (2025). Early Diagnosis of Ovarian Cancer: A Comprehensive Review of the Advances, Challenges, and Future Directions. Diagnostics, 15(4), 406. https://doi.org/10.3390/diagnostics15040406
Huang, J., Chan, W. C., Ngai, C. H., Lok, V., Zhang, L., Lucero-Prisno, D. E., Xu, W., Zheng, Z.-J., Edmar Elcarte, Withers, M., & Martin. (2022). Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study. Cancers, 14(9), 2230–2230. https://doi.org/10.3390/cancers14092230
Johns Hopkins Medicine. (2024). AI “Liquid Biopsies” Using Cell-Free DNA, Protein Biomarkers, Could Aid Early Detection of Ovarian Cancer. Hopkinsmedicine.org. https://www.hopkinsmedicine.org/news/newsroom/news-releases/2024/09/ai-liquid-biopsies-using-cell-free-dna-protein-biomarkers-could-aid-early-detection-of-ovarian-cancer
Leo, A. D., Santini, D., Ceccarelli, C., Santandrea, G., Palicelli, A., Acquaviva, G., Chiarucci, F., Rosini, F., Ravegnini, G., Pession, A., Turchetti, D., Zamagni, C., Perrone, A. M., Pierandrea De Iaco, Tallini, G., & Biase, D. de. (2021). What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors. Diagnostics, 11(4), 697–697. https://doi.org/10.3390/diagnostics11040697
Li, T., Zhang, H., Lian, M., He, Q., Lv, M., Zhai, L., Zhou, J., Wu, K., & Yi, M. (2025). Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021. Journal of Hematology & Oncology, 18(1). https://doi.org/10.1186/s13045-025-01660-y
Li, X., Li, Z., Ma, H., Li, X., Zhai, H., Li, X., Cheng, X., Zhao, X., Zhao, Z., & Hao, Z. (2024). Ovarian cancer: Diagnosis and treatment strategies (Review). Oncology Letters, 28(3). https://doi.org/10.3892/ol.2024.14574
Liberto, J. M., Chen, S.-Y., Shih, I.-M., Wang, T.-H., Wang, T.-L., & Pisanic, T. R. (2022). Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review. Cancers, 14(12), 2885–2885. https://doi.org/10.3390/cancers14122885
Liu, X., & Han, Y. (2025). Diagnostic value of transvaginal ultrasound combined with serum CA125 and HE4 in differentiating benign and malignant ovarian tumors. European Journal of Gynaecological Oncology, 46(5), 130–130. https://doi.org/10.22514/ejgo.2025.073
Maioru, O.-V., Radoi, V.-E., Coman, M.-C., Hotinceanu, I.-A., Dan, A., Eftenoiu, A.-E., Burtavel, L.-M., Bohiltea, L.-C., & Severin, E.-M. (2023). Developments in Genetics: Better Management of Ovarian Cancer Patients. International Journal of Molecular Sciences, 24(21), 15987. https://doi.org/10.3390/ijms242115987
Mallya, M., Mirabadi, A. K., Farahani, H., & Bashashati, A. (2024). Benchmarking Histopathology Foundation Models for Ovarian Cancer Bevacizumab Treatment Response Prediction from Whole Slide Images. ArXiv.org. https://arxiv.org/abs/2407.20596
Métairie, M., Benoit, L., Meriem Koual, Bentivegna, E., Henri Wohrer, Bolze, P.-A., Yohan Kerbage, Raimond, E., Cherif Akladios, Carcopino, X., Geoffroy Canlorbe, Uzan, J., Lavoué, V., Mimoun, C., Cyrille Huchon, Koskas, M., Hélène Costaz, François Margueritte, Yohann Dabi, & Touboul, C. (2023). A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer. Cancers, 15(3), 706–706. https://doi.org/10.3390/cancers15030706
Xiao, Y., & Hua Linghu. (2023). Survival Outcomes of Patients with International Federation of Gynecology and Obstetrics Stage IV Ovarian Cancer: Cytoreduction Still Matters. Cancer Control, 30. https://doi.org/10.1177/10732748231159778
Reid, F., Bajwa, A., & Assistant, R. (2023). THE WORLD OVARIAN CANCER COALITION ATLAS 2023 GLOBAL TRENDS IN INCIDENCE, MORTALITY, AND SURVIVAL. https://worldovariancancercoalition.org/wp-content/uploads/2023/04/World-Ovarian-Cancer-Coalition-Atlas-2023-FINAL.pdf
Smith, A. J. B., Alvarez, R., Heintz, J., Simpkins, F., & Ko, E. M. (2023). Disparities in clinical trial participation in ovarian cancer: A real-world analysis. Gynecologic Oncology, 175, 25–31. https://doi.org/10.1016/j.ygyno.2023.05.066
Tew, W. P., Lacchetti, C., Ellis, A., Maxian, K., Banerjee, S., Bookman, M., Jones, M. B., Lee, J.-M., Lheureux, S., Liu, J. F., Moore, K. N., Muller, C., Rodriguez, P., Walsh, C., Westin, S. N., & Kohn, E. C. (2020). PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. Journal of Clinical Oncology, 38(30), 3468–3493. https://doi.org/10.1200/jco.20.01924
Wang, Y., Wang, Z., Zhang, Z., Wang, H., Peng, J., & Hong, L. (2023). Burden of ovarian cancer in China from 1990 to 2030: A systematic analysis and comparison with the global level. Frontiers in Public Health, 11. https://doi.org/10.3389/fpubh.2023.1136596
Xiao, Y., & Linghu, H. (2023). Survival Outcomes of Patients with International Federation of Gynecology and Obstetrics Stage IV Ovarian Cancer: Cytoreduction Still Matters. Cancer C Liu, Z., Jing, C., & Kong, F. (2024). From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer. Journal of Ovarian Research, 17(1). https://doi.org/10.1186/s13048-024-01359-7
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Łukasz Woźniak, Albert Lompart, Michał Wabiszczewicz, Albert Kosarewicz, Patrycja Krysiak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 291
Number of citations: 0
